Published in Drug Week, April 1st, 2005
The data suggests that patients with acutely decompensated chronic heart failure may benefit from the first of its kind Cancion therapy. Based on Orqis Medical's proprietary discoveries in hemodynamic principles, the therapy is designed to create a unique "rest to recovery" environment that enable the failing heart to rest as it continues to function.
It represents a significant departure from conventional drug therapy...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.